133 related articles for article (PubMed ID: 22050597)
1. Translating clinical activity and gene expression signatures of etanercept and ciclosporin to the psoriasis xenograft SCID mouse model.
Norsgaard H; Svensson L; Hagedorn PH; Moller K; Olsen GM; Labuda T
Br J Dermatol; 2012 Mar; 166(3):649-52. PubMed ID: 22050597
[TBL] [Abstract][Full Text] [Related]
2. The psoriasis xenograft SCID mouse model: a tool in translational research.
Boehncke WH
Br J Dermatol; 2012 Mar; 166(3):473. PubMed ID: 22356635
[No Abstract] [Full Text] [Related]
3. Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24.
Wang F; Smith N; Maier L; Xia W; Hammerberg C; Chubb H; Chen C; Riblett M; Johnston A; Gudjonsson JE; Helfrich Y; Kang S; Fisher GJ; Voorhees JJ
Br J Dermatol; 2012 Jul; 167(1):92-102. PubMed ID: 22458549
[TBL] [Abstract][Full Text] [Related]
4. Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks.
Gambichler T; Tigges C; Scola N; Weber J; Skrygan M; Bechara FG; Altmeyer P; Kreuter A
Br J Dermatol; 2011 Jun; 164(6):1383-6. PubMed ID: 21466532
[TBL] [Abstract][Full Text] [Related]
5. Initial experience with routine administration of etanercept in psoriasis.
de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
[TBL] [Abstract][Full Text] [Related]
6. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
[TBL] [Abstract][Full Text] [Related]
7. Statistical evaluation and experimental design of a psoriasis xenograft transplantation model treated with cyclosporin A.
Stenderup K; Rosada C; Alifrangis L; Andersen S; Dam TN
Exp Dermatol; 2011 May; 20(5):441-4. PubMed ID: 21426413
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.
Sterry W; Ortonne JP; Kirkham B; Brocq O; Robertson D; Pedersen RD; Estojak J; Molta CT; Freundlich B
BMJ; 2010 Feb; 340():c147. PubMed ID: 20124563
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
10. Two years of experience with etanercept in recalcitrant psoriasis.
Ahmad K; Rogers S
Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393
[TBL] [Abstract][Full Text] [Related]
11. CTACK /CCL27 expression in psoriatic skin and its modification after administration of etanercept.
Campanati A; Goteri G; Simonetti O; Ganzetti G; Giuliodori K; Stramazzotti D; Morichetti D; Bernardini ML; Mannello B; Fabris G; Offidani A
Br J Dermatol; 2007 Dec; 157(6):1155-60. PubMed ID: 17916208
[TBL] [Abstract][Full Text] [Related]
12. Etanercept combined with methotrexate for high-need psoriasis.
Driessen RJ; van de Kerkhof PC; de Jong EM
Br J Dermatol; 2008 Aug; 159(2):460-3. PubMed ID: 18547310
[TBL] [Abstract][Full Text] [Related]
13. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A
Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
[TBL] [Abstract][Full Text] [Related]
15. Th1, Th2, Th17 and regulatory T cell pattern in psoriatic patients: modulation of cytokines and gene targets induced by etanercept treatment and correlation with clinical response.
Quaglino P; Bergallo M; Ponti R; Barberio E; Cicchelli S; Buffa E; Comessatti A; Costa C; Terlizzi ME; Astegiano S; Novelli M; Cavallo R; Bernengo MG
Dermatology; 2011; 223(1):57-67. PubMed ID: 21865674
[TBL] [Abstract][Full Text] [Related]
16. The use of ciclosporin in psoriasis.
Berth-Jones J
J Dermatolog Treat; 2005; 16(5-6):258-77. PubMed ID: 16428145
[TBL] [Abstract][Full Text] [Related]
17. Etanercept does not have an apoptosis-inducing effect on psoriatic keratinocytes.
Tatlican S; Arikok A; Gulbahar O; Eren C; Cevirgen B; Eskioglu F
J Dermatolog Treat; 2010 Sep; 21(5):306-10. PubMed ID: 19878038
[TBL] [Abstract][Full Text] [Related]
18. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
Kircik LH
J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
[TBL] [Abstract][Full Text] [Related]
19. Etanercept for the treatment of psoriasis: combination therapy with other modalities.
Strober BE; Clarke S
J Drugs Dermatol; 2004; 3(3):270-2. PubMed ID: 15176161
[TBL] [Abstract][Full Text] [Related]
20. Etanercept: an evolving role in psoriasis and psoriatic arthritis.
Prodanovich S; Ricotti C; Glick BP; Inverardi L; Leonardi CL; Kerdel F
Am J Clin Dermatol; 2010; 11 Suppl 1():3-9. PubMed ID: 20586498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
